Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1529-1536

  Rezai, Keyvan ^a   Urien, S ^a,b   Isambert, N ^c,d   Roche, H ^e   Dieras, V ^a   Berille, J ^f   Bonneterre, J ^g   Brain, E ^a   Lokiec, F ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f FNCLCC   (France)

^g CENTRE OSCAR LAMBRET   (France)

Author keywords

Anti cancer agents; Drug interactions; Lapatinib; Population pharmacokinetics; Vinorelbine

Indexed keywords

LAPATINIB; NAVELBINE;

ADULT; AGED; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; COMPARTMENT MODEL; CONFUSION; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; MULTIVISCERAL FAILURE; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINAZOLINES; VINBLASTINE;

EID: 82455175175     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1650-8     Document Type: Article

References (17)

1. XJ Zhou R Rahmani 1992 Preclinical and clinical pharmacology of vinca alkaloids Drugs 44 Suppl 4 1 1283846 10.2165/00003495-199200444-00002 1:CAS:528:DyaK3sXhtl2jtL4%3D
2. RK Gregory IE Smith 2000 Vinorelbine: a clinical review Br J Cancer 82 1907 10864196 10.1054/bjoc.2000.1203 1:CAS:528:DC%2BD3cXksVChs7s%3D
3. JP Crown HA Burris III F Boyle S Jones M Koehler BO Newstat R Parikh C Oliva A Preston J Byrne 2008 Pooled analysis of diarrhea events in patients with cancer treated with lapatinib Breast Cancer Res Treat 112 317 18204897 10.1007/s10549-007-9860-9 1:CAS:528:DC%2BD1cXht1Cms73P
4. Gomez HL, Chavez MA, Doval DC, (2006). Results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast cancer Res Treat 100:S68. Abstract 1090
5. HL Gomez DC Doval MA Chavez PC Ang Z Aziz S Nag C Ng SX Franco LW Chow MC Arbushites MA Casey MS Berger SH Stein GW Sledge 2008 Efficacy and safety of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer J Clin Oncol 26 2999 18458039 10.1200/JCO.2007.14.0590 1:CAS:528:DC%2BD1cXoslOqsLo%3D
6. WC Teng JW Oh LS New MD Wahlin SD Nelson HK Ho ECY Chan 2010 Mechanism-Based inactivation of cytochrome P450 3A4 by lapatinib Mol Pharmacol 78 693 20624855 10.1124/mol.110.065839 1:CAS:528:DC%2BC3cXht1eisLrI
7. L Nguyen B Tranchand C Puozzo P Variol 2001 Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials Br J Clin Pharmacol 53 459 10.1046/j.1365-2125.2002. 01581.x
8. Van Heugen JC, De Graeve J, Zorza G, Puozzo C (2001) New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 926:11
9. F Bai BB Freeman III CH Fraga 2006 Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) J Chromatogr B Anal Technol Biomed Life Sci 831 169 10.1016/j.jchromb.2005.11.044 1:CAS:528:DC%2BD28Xos1SgsQ%3D%3D (Pubitemid 43155792)
10. E Kuhn, et al. 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 1020 1030 10.1016/j.csda.2004.07.002 (Pubitemid 40710158)
11. Development Core R, Team R (2009) A language and environment for statistical computing. R Foundation for Statistical Computin. Vienna, Austria
12. K Brendel, et al. 2010 Evaluation of different tests based on observations for external model evaluation of population analyses J Pharmacokinet Pharmacodyn 37 49 65 20033477 10.1007/s10928-009-9143-7
13. S Urien F Brée F Breillout G Bastian A Krikorian JP Tillement 1993 Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood Cancer Chemother Pharmacol 32 231 8500229 10.1007/BF00685841 1:CAS:528:DyaK3sXlslemt7k%3D
14. Puozzo C, Gridelli C (2004) Non-small-cell lung cancer in elderly patients: Influence of age on vinorelbine oral pharmacokinetics. Clinical Lung Cancer 237
15. Khayat D, Rixe O, Brunet R, Goupil A, Bugat R, Harousseau JL, Ifrah N, Puozzo C (2004). Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54:193
16. M Wong RL Balleine EYL Blair AJ McLachlan SP Ackland MB Grag S Evans D Farlow M Collins LP Rivory JM Hoskins GJ Mann CL Clarke H Gurney 2006 Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer J Clin Oncol 24 2448 16651648 10.1200/JCO.2005.02.1295 1:CAS:528: DC%2BD28XmtVOmsb0%3D (Pubitemid 46630621)
17. B Thiessen C Stewart M Tsao S Kamel-Reid P Schiaquevich W Mason K Belanger P Forsyth L McIntosh E Eisenhauer 2010 A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation Cancer Chemother Pharmacol 65 353 19499221 10.1007/s00280-009-1041-6 1:CAS:528:DC%2BD1MXhsVKnsL7K